Data showing that the location of EGFR exon 20 insertion mutations impacts patients' responses to Spectrum's poziotinib could have implications for other EGFR inhibitors.
The company is conducting a clinical trial of a pan-variant inhibitor for KIT-mutant GIST and hopes to advance an EGFR pan-variant inhibitor to the clinic soon.